SIRT7 inhibitor 97491 NEW
| Price | $97 | $247 | $372 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: SIRT7 inhibitor 97491 | CAS No.: 1807758-81-1 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | SIRT7 inhibitor 97491 |
| Description | SIRT7 inhibitor 97491 is an HDAC inhibitor with high specificity for SIRT7 (IC50 = 325 nM). SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. |
| In vitro | SIRT7 inhibitor 97491 (1-10 μM) effectively reduces the proliferation of human uterine sarcoma MES-SA cells by over 50% at 5 and 10 μM after 72 hours, without cytotoxic effects on HEK293 human embryonic kidney cells after 24 hours of exposure, indicating selective action[1]. |
| In vivo | The SIRT7 inhibitor 97491 (2 mg/kg; intraperitoneally injected; for 3 weeks, except on weekends) effectively suppresses tumor growth in xenograft mice[1]. Utilizing Balb/c nude mice (18-20 g; 6-8 weeks old) implanted with MES-SA cells[1], the dosage administered was 2 mg/kg via intraperitoneal injection over a three-week period, excluding weekends. The outcome was a significant inhibition of cancer growth in vivo. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 500 mg/mL (1749.9 mM), Sonication is recommended. |
| Keywords | tumor | Sirtuin | SIRT-7 inhibitor 97491 | SIRT7 inhibitor 97491 | SIRT7 | p53 K373/382 | Inhibitor | inhibit | deacetylase | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Glutamine Metabolism Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-11-10 | |
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-19 | |
| $0.00/200kg |
VIP3Y
|
Nanjing Huazhou New Material Co., Ltd.
|
2024-02-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY